Abstract
In the congestive heart failure state, autonomic dysregulation involves an increase in sympathetic tone and decrease in parasympathetic tone and is associated with increased mortality. It is possible that augmentation of the parasympathetic nervous system (PNS) with pharmacologic therapy may lead to improved symptoms and/or clinical outcomes. There are several new and established pharmacologic interventions that have been studied for their effect on the PNS, including antagonists of the renin–angiotensin system, beta-adrenergic antagonists, digoxin, and vasodilators. In this review, we discuss the current status of the published literature on pharmacologic influences on the PNS by both conventional and experimental drugs targeting heart failure as well as drugs that more directly influence vagal tone. While these analyses have been largely limited to putative surrogates for clinical outcomes like heart rate variability, and it is often difficult to differentiate between indirect and direct pharmacologic effects on the PNS, significant insight into potential mechanisms of action can be derived. The future evaluation of drugs in development for heart failure treatment should include a careful, scientifically sound exploration of the potential impact of the intervention on PNS activity.
Similar content being viewed by others
References
Olshansky B, Sabbah N, Hauptman PJ, Colucci WS (2008) The parasympathetic nervous system and heart failure: pathophysiology and implications for therapy. Circulation 118:863–871
Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, Campana C, Revera M, Ajmone-Marsan N, Tavazzi L, Odero A (2008) Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail 10:884–891
Osterziel K, Dietz R (1996) Improvement of vagal tone by ACE inhibition: a mechanism of cardioprotection in patients with mild-to-moderate heart failure. J Cardiovasc Pharmacol 27(2):25–30
Osterziel K, Rohrig N, Dietz R, Manthey J, Hecht J, Kubler W (1988) Influence of captopril on the arterial baroreceptor reflex in patients with heart failure. Eur Heart J 9:1137–1145
Task Force of the European Society of Cardiology and the North American Society of Pacing Electrophysiology (1996) Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation 93:1043–1065
Miyashita Y, Furukawa Y, Nakajima K, Hirose M, Kurogouchi F, Chiba S (1999) Parasympathetic inhibition of sympathetic effects on pacemaker location and rate in hearts of anesthetized dogs. J Cardiovasc Electrophysiol 10(8):1066–1076
Colucci WS (1990) In vivo studies of myocardial beta-adrenergic receptor pharmacology in patients with congestive heart failure. Circulation 82(2 Suppl):I44–I51
Khamssi M, Brodde OE (1990) The role of cardiac beta1- and beta2-adrenoceptor stimulation in heart failure. J Cardiovasc Pharmacol 16(Suppl 5):S133–S137
Janse MJ (2004) Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc Res 61(2):208–217
Palatini P (2001) Heart rate as a cardiovascular risk factor: do women differ from men? Ann Med 33(4):213–221
Hjalmarson A (1998) Significance of reduction in heart rate in cardiovascular disease. Clin Cardiol 21(12 Suppl 2):II3–II7
Brown MD, Davies MK, Hudlicka O (2005) Angiogenesis in ischaemic and hypertrophic hearts induced by long-term bradycardia. Angiogenesis 8(3):253–262. Epub 2005 Nov 25
Flannery G, Gehrig-Mills R, Billah B, Krum H (2008) Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 101(6):865–869. Epub 2008 Feb 21
Alboni P, Scarfò S, Fucà G (2001) Development of heart failure in bradycardic sick sinus syndrome. Ital Heart J 2(1):9–12
Wolf MM, Varigos GA, Hunt D, Sloman JG (1978) Sinus arrhythmia in acute myocardial infarction. Med J Aust 2(2):52–53
Akselrod S, Gordon D, Ubel FA, Shannon DC, Barger AC, Cohen RJ (1981) Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat to beat cardiovascular control. Science 213:220–222
Coumel P, Maison-Blanche P, Catuli D et al (1994) Heart rate and heart rate variability in normal young adults. J Cardiovasc Electrophysiol 5:899–911
Malik M (2004) Standard measurement of heart rate variability in dynamic electrocardiography. In: Malik M, Camm AJ (eds) Dynamic electrocardiography. Blackwell Futura, Malden, MA
Guzik P, Piskorski J, Krauze T, Schneider R, Wesseling KH, Wykretowicz A, Wysocki H (2007) Correlations between the Poincaré plot and conventional heart rate variability parameters assessed during paced breathing. J Physiol Sci 57(1):63–71
Pagani M, Lombardi F, Guzzetti S et al (1986) Power spectral analysis of heart rate and arterial pressure variabilities as a marker of smypatho-vagal interaction in man and conscious dog. Circ Res 59:178–193
Steptoe A, Vögele C (1990) Cardiac baroreflex function during postural change assessed using non-invasive spontaneous sequence analysis in young men. Cardiovasc Res 24(8):627–632
Frankel RA, Metting PJ, Britton SL (1993) Evaluation of spontaneous baroreflex sensitivity in conscious dogs. J Physiol 462:31–45
Ducher M, Fauvel JP, Gustin MP, Cerutti C, Najem R, Cuisinaud G, Laville M, Pozet N, Paultre CZ (1995) A new non-invasive statistical method to assess the spontaneous cardiac baroreflex in humans. Clin Sci (Lond) 88(6):651–655
Watanabe MA, Schmidt G (2004) Heart rate turbulence: a 5-year review. Heart Rhythm 6:732–738
Schmidt G, Malik M, Barthel P, Schneider R, Ulm K, Rolnitzky L, Camm JA, Bigger JT Jr, Schömig A (1999) Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet 353:1390–1396
Ghuran A, Reid F, La Rovere MT, Schmidt G, Bigger JT Jr, Camm AJ, Schwartz PJ, Malik M (2002) ATRAMI Investigators. Heart rate turbulence-based predictors of fatal and nonfatal cardiac arrest (The autonomic tone and reflexes after myocardial infarction substudy). Am J Cardiol 89:184–190
Barthel P, Schneider R, Bauer A, Ulm K, Schmitt C, Schömig A, Schmidt G (2003) Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation 108(10):1221–1226. Epub 2003 Aug 25
Sade E, Aytemir K, Oto A, Nazli N, Ozmen F, Ozkutlu H, Tokgözoglu L, Aksöyek S, Ovünç K, Kabakçi G, Ozer N, Kes S (2003) Assessment of heart rate turbulence in the acute phase of myocardial infarction for long-term prognosis. Pacing Clin Electrophysiol 26(2 Pt 1):544–550
Flapan A, Nolan J, Neilson J, Ewing D (1992) Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Am J Cardiol 69:532–535
Binkley P, Haas G, Starling R, Nunziata E, Hatton P, Leier C, Cody R (1993) Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. JACC 21(3):655–661
Zhang Y, Song Y, Jun Z, Tao-hong H, Li-li W (1995) Effects of enalapril on heart rate variability in patients with congestive heart failure. Am J Cardiol 76:1045–1048
Guedon-Moreau L, Pinaud A, Logier R, Caron J, Lekieffre J, Dupuis B, Libersa C (1997) Effect of ramipril on heart rate variability in digitalis-treated patients with chronic heart failure. Cardiovasc Drugs Ther 11:531–536
Kamen P, Krum H, Tonkin A (1997) Low-dose but not high-dose captopril increases parasympathetic activity in patients with heart failure. J Cardiovasc Pharmacol 30(1):7–11
Adigun A, Asiyanbola B, Ajayi A (2001) Cardiac autonomic function in blacks with congestive heart failure: vagomimetic action, alteration in sympathovagal balance, and the effect of ACE inhibition on central and peripheral vagal tone. Cell Mol Biol 47(6):1063–1066
Ondocin P, Narsipur S (2006) Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis. Nephrology 11:497–501
Dibona G, Jones S, Sawin L (1998) Angiotensin receptor antagonist improves cardiac reflex control of renal sodium handling in heart failure. Am J Physiol Heart Circ Physiol 274:636–641
Tambara K, Fujita M, Sumita Y, Miyamoto S, Sekiguchi H, Eiho S, Komeda M (2004) Beneficial effect of candesartan treatment on cardiac autonomic nervous activity in patients with chronic heart failure: simultaneous recording of ambulatory electrocardiogram and posture. Clin Cardiol 27:300–303
Petretta M, Spinelli L, Marciano F, Apicella C, Vicario M, Testa G, Volpe M, Bonaduce D (2000) Effects of losartan treatment on cardiac autonomic control during volume loading in patients with DCM. Am J Physiol Heart Circ Physiol 279:86–92
Ozdemir M, Arslan U, Turkoglu S, Balcioglu S, Cengel A (2007) Losartan improves heart rate variability and heart rate turbulence in heart failure due to ischemic cardiomyopathy. J Cardiac Fail 13:812–817
Vaile J, Chowdhary S, Osman F, Ross H, Fletcher J, Littler W, Coote J, Townend J (2001) Effects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure. Clin Sci 101:559–566
De Tommasi E, Iacoviello M, Romito R, Ceconi C, Guida P, Massari F, Francolini G, Bertocchi F, Ferrari R, Rizzon P, Pitzalis M (2003) Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am Heart J 146:e17
MacFadyen R, Barr C, Struthers A (1997) Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35:30–34
Yee K, Pringle S, Allan D, Struthers A (2001) Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 37:1800–1807
Korkmaz M, Muderrisoglu H, Ulucam M, Ozin B (2000) Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am J Cardiol 86:649–653
Shehab A, Elnour A, Struthers A (2008) A randomized, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. Cardiovasc J Afr 19:292–296
Farquharson C, Struthers A (2002) Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart 88:475–480
Sal’nikov E (2009) Heart rate variability in rats with experimental chronic heart failure and long-term exposure to β-adrenoblockers. Bull Exp Biol Med 147(2):181–184
Akdeniz B, Guneri S, Savas I, Aslan O, Baris N, Badak O, Kirimli O, Goldeli O (2006) Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure. Int Heart J 47:565–573
Hennersdorf M, Perings C, Vester E (1999) Hemodynamic effects of celiprolol in patients with ischemic and non-ischemic cardiomyopathy. Int J Cardiol 68:289–295
Copie X, Pousset F, Lechat P, Jaillon P, Guize L, Le Heuzey J (1996) Effects of beta-blockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of R-R intervals at selected heart rates. Am Heart J 132:369–375
Bullinga J, Alharethi R, Schram M, Bristow M, Gilbert E (2005) Changes in heart rate variability are correlated to hemodynamic improvement with chronic carvedilol therapy in heart failure. J Card Fail 11:693–699
Piccirillo G, Leonetti R, Celli V, Moise A, Lionetti M, Marigliano V, Cacciafesta A (2000) Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure. Am J Cardiol 86:1392–1395
Goldsmith R, Bigger J, Bloomfield D, Krum H, Steinman R, Sackner-Bernstein J, Packer M (1997) Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol 80:1101–1104
Aronson D, Burger A (2001) Effect of beta blockade on autonomic modulation of heart rate and neurohormonal profile in decompensated heart failure. A.N.E 6(2):98–106
Tjeerdsma G, Szabo B, Wijk L, Brouwer J, Tio R, Crijns H, Veldhuisen D (2001) Autonomic dysfunction in patients with mild heart failure and coronary artery disease and the effects of add-on B-blockade. Eur J Heart Fail 3:33–39
Pousset F, Copie X, Lechat P, Jaillon P, Boissel J, Hetzel M, Fillette F, Remme W, Guize L, Le Heuzey J (1996) Effects of bisprolol on heart rate variability in heart failure. Am J Cardiol 77:612–617
Mortara A, La Rovere M, Pinna G, Maestri R, Capomolla S, Cobelli F (2000) Nonselective beta- adrenergic blocking agent, carvedilol, improves arterial baroreflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 36:1612–1618
Aquilante C, Terra S, Schofield R, Pauly D, Hatton P, Binkley P, Johnson J (2006) Sustained restoration of autonomic balance with long but not short acting metoprolol in patients with heart failure. J Card Fail 12(3):171–176
Tygesen H, Andersson B, Di Lenarda A, Rundqvist B, Sinagra G, Hjalmarson A, Waagstein F, Wennerblom B (1999) Potential risk of b-blockade withdrawal in congestive heart failure due to abrupt autonomic changes. Int J Cardiol 68:171–177
Lin J, Chan H, Du C, Lin I, Lai C, Lin K, Wu C, Tseng Y, Lien W (1999) Long-term beta-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study. Am Heart J 137(4):658–665
Lin L, Hwang J, Lai L, Chan H, Du C, Tseng Y, Lin J (2004) Restoration of heart rate turbulence by titrated beta-blocker therapy in patients with advanced congestive heart failure: positive correlation with enhanced vagal modulation of heart rate. J Cardiovasc Electrophysiol 15:752–756
Kubo T, Parker J, Azevedo E, Atchison D, Newton G, Picton P, Floras J (2005) Vagal heart rate responses to chronic beta-blockade in human heart failure to cardiac norepinephrine spillover. Eur J Heart Fail 7:878–881
Racine N, Blanchet M, Ducharme A, Marquis J, Boucher J, Juneau M, White M (2003) Decreased heart rate recovery after exercise in patients with congestive heart failure: effect of beta blocker therapy. J Card Fail 9(4):296–302
Sanderson J, Yeung L, Chan S, Tomlinson B, Kay R, Woo K, Bernardi L (1999) Effect of b-blockade on baroreceptor and autonomic function in heart failure. Clin Sci 96:137–146
Sanderson J, Chan S, Yip G, Yeung L, Chan K, Raymond K, Woo K (1999) Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 34:1522–1528
Hamaad A, Lip G, Nicholls D, MacFadyen R (2007) Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure. Cardiovasc Drugs Ther 21:437–444
Girgis I, Chakko S, de Marchena E, Jara C, Diaz P, Castellanos A, Myerburg R (1998) Effect of clonidine on heart rate variability in congestive heart failure. Am J Cardiol 82:335–337
You-hua Z, You-cheng S, Jun Z, Xian-qi Y (1997) Sympathetic inhibition with clonidine improves autonomic balance in congestive heart failure. Int J Cardiol 59:139–144
Cohn J, Pfeffer M, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright T (2003) Adverse mortality effect of central sympathetic inhibition with sustained release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5:659–667
Dickstein K, Manhenke C, Aarsland T, McNay J, Wiltse C, Wright T (2000) The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure. Int J Cardiol 75:167–176
Hauptman PJ, Kelly RA (2007) Digitalis Glycosides. In: Hosenpud JD, Greenberg BH (eds) Congestive heart failure, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 449–466
Krum H, Bigger J, Goldsmith R, Packer M (1995) Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 25:289–294
Vardas P, Kanoupakis E, Kochiadakis G, Simantirakis E, Marketou M, Chlouverakis G (1998) Effects of long-term digoxin therapy on heart rate variability, baroreceptor sensitivity, and exercise capacity in patients with heart failure. Cardiovasc Drugs Ther 12:47–55
Slatton M, Irani W, Hall S, Marcoux L, Page R, Grayburn P, Eichhorn E (1997) Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? J Am Coll Cardiol 29:1206–1213
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289:871–878
Szabo B, Van Veldhuisen D, Van Der Burgh P, Kruik J, Girbes A, Lie K (1996) Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. J Card Fail 2(3):185–192
Brouwer J, Van Veldhuisen D, Man in’t Veld A, Dunselman P, Boomsma F, Haaksma J, Lie K (1995) Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. J Am Coll Cardiol 26:983–990
Aronson D, Burger A (2004) Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure. Am Heart J 148:e16
Buch A, Chowdhary S, Coote J, Townend J (2004) Effects of nitroglycerin treatment on cardiac autonomic control in heart failure. Clin Auton Res 14:9–14
Pliquett R, Cornish K, Zucker I (2003) Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 95:700–704
Gao L, Wang W, Li Y, Schultz H, Liu D, Cornish K, Zucker I (2005) Simvastatin therapy normalizes sympathetic neural control in experimental heart failure roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 112:1763–1770
Katircibasi M, Canatar T, Kocum H, Erol T, Tekin G, Demircan S, Tekin A, Sezgin A, Baltali M, Muderrisoglu H (2005) Decreased heart rate recovery in patients with heart failure effect of fluvastatin therapy. Int Heart J 46:845–854
Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Radovancevic B (2005) Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 11(9):684–690
Hamaad A, Sosin M, Lip G, MacFadyen R (2005) Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure. Cardiovasc Drugs Ther 19:183–187
Gentlesk P, Wiley T, Taylor A (2005) A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. Am Heart J 150:478–483
Zuanetti J, Latini R, Neilson J, Schwartz P, Ewing D (1991) Heart rate variability in patients with ventricular arrhythmias: effects of antiarrhythmic drugs. J Am Coll Cardiol 17:1–604
Rohde L, Polanczyk C, Moraes R, Ferlin E, Ribeiro J (1998) Effect of partial arrhythmia suppression with amiodarone on heart rate variability of patients with congestive heart failure. Am Heart J 136:31–36
Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN (1985) Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med 103:1–6
Tomiyama H, Nakayama T, Watanabe G, Shiojima K, Sakuma Y, Yamamoto A, Imai Y, Yoshida H, Doba N (1999) Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure. Am Heart J 137:543–548
Shehab A, Butler R, MacFadyen R, Struthers A (2001) A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure. Br J Clin Pharmacol 51:329–334
Radaelli A, Cazzaniga M, Viola A, Balestri G, Janetti M, Signorini M, Castiglioni P, Azzellino A, Mancia G, Ferrari A (2006) Enhanced baroreceptor control of the cardiovascular system by polyunsaturated fatty acids in heart failure patients. J Am Coll Cardiol 48:1600–1606
Giannattasio C, Failla M, Stella ML et al (1995) Alterations of radial artery compliance in patients with congestive heart failure. Am J Cardiol 76:381–385
Holguin F, Tellez-Rojo M, Lazo M, Mannino D, Schwartz J, Hernandez J, Romieu I (2005) Cardiac autonomic changes associated with fish oil vs soy oil supplementation in the elderly. Chest 127:1102–1107
Mangin L, Swynghedauw B, Benis A, Thibault N, Lerebours G, Carre F (1998) Relationships between heart rate and heart rate variability: study in conscious rats. J Cardiovasc Pharmacol 32(4):601–607
Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 372:807–816
Swedberg K, Kamajda M, Bohm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet 376:875–885
Behling A, Moraes R, Rohde L, Ferlin E, No′brega A, Ribeiro J (2003) Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure. Am Heart J 146:494–500
Serra S, Costa R, Castro R, Xavier S, Da Nobrega A (2009) Cholinergic stimulation improves autonomic and hemodynamic profile during dynamic exercise in patients with heart failure. J Card Fail 15:124–129
Hayano T, Shimizu A, Ikeda Y, Yamamoto T, Yamagata T, Ueyama T, Furutani Y, Matsuzaki M (1999) Paradoxical effects of pirenzepine on parasympathetic activity in chronic heart failure and control. Int J Cardiol 68:47–56
Venkatesh G, Fallen E, Kamath M, Connolly S, Yusuf S (1996) Double blind placebo controlled trial of transdermal scopolamine on heart rate variability in short term patients with chronic heart failure. Heart 76:137–143
Jacoby DB, Gleich GJ, Fryer AD (1993) Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest 91:1314–1318
Casadei B, Conway J, Forfar C, Sleight P (1996) Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure. Heart 75:274–280
La Rovere M, Mortara A, Pantaleo P, Maestri R, Cobelli F, Tavazzi L (1994) Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation 90:838–843
Okazaki Y, Zheng C, Li M, Sugimachi M (2010) Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. J Physiol Sci 60:67–74
Masuda Y, Kawamura A (2003) Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability. J Cardiovasc Pharmacol 41(Suppl. 1):567–571
McLaren A, Allen J, Murray A, Ballard C, Kenny R (2003) Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 15:183–188
Giubilei F, Strano S, Imbimbo P, Tisei P, Calcagnini G, Lino S, Frontoni M, Santini M, Fieschi C (1998) Cardiac autonomic dysfunction in patients with Alzheimer disease: possible pathogenetic mechanisms. Alzheimer Dis Assoc Disord 12(4):356–361
Siepmann M, Muck A, Engel S, Rupprecht R, Muck-Weymann M (2006) The influence of rivastigmine and donepezil on heart rate variability in patients with Alzheimer’s disease. German J Psych 9:133–135
Bibevski S, Dunlap M (2004) Prevention of diminished parasympathetic control of the heart in experimental heart failure. Am J Physiol Heart Circ Physiol 287:H1780–H1785
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Desai, M.Y., Watanabe, M.A., Laddu, A.A. et al. Pharmacologic modulation of parasympathetic activity in heart failure. Heart Fail Rev 16, 179–193 (2011). https://doi.org/10.1007/s10741-010-9195-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-010-9195-1